ASH News Daily 2017 - Issue 1 - B-22

Page B-22

ASH News Daily

Saturday, December 9, 2017

Blood

«« From Page B-1

and represents high-quality information. Given this and the historical importance of Blood for the hematology community, it is an honor
to be able to evaluate manuscripts
under consideration at Blood.
Meletios Dimopoulos: My motivation stems from knowing that
Blood is one of the most prestigious
journals in medicine. For that reason, I consider it a great honor to
serve as a reviewer.
What single factor do you most enjoy about the process of peer review;
what aspect most surprised you when
you first joined?
OA-W: I enjoy evaluating research findings at their earliest pos-

A manuscript submitted
to Blood should contain
novel information that
will advance the
knowledge in a
particular field.
sible point of introduction to the
public and learning how others
present their data to a wider audience. I believe this has made me a
better writer and presenter of my
own work.
MD: I'm always interested to see
new data that have never been published before. This also helps me to
stay up to date on the most recent
developments in the field of plasma
cell dyscrasias.
Balancing informed criticism with
sensitivity and a constructive attitude
toward peers is key, yet not always
easy. How do you manage to achieve
this during your manuscript reviews?
OA-W: This is something that
actually becomes easier with more
experience reviewing papers for a
single journal. One begins to see the
level of evidence and data required
for a typical publication to be accepted at Blood, and this provides a
benchmark to evaluate future manuscripts under consideration.
MD: My goal is to be fair in my
reviews at all times, while keeping
in mind that only a minority of submitted papers can be accepted in a

ASH Foundation
Run/Walk Is Set
for Tomorrow
The fifth annual ASH Foundation Run/Walk will take place
tomorrow, December 10, 2017.
To register, visit the Race Registration Counter located in
ASH Central (Hall B1) by 6:00
p.m. today!

high-quality journal such as Blood.
Is there particular advice that you
would offer manuscript authors with
limited experience?
OA-W: It is so important to have
your manuscript carefully read by
others who have been less involved
in the study and have less prior
knowledge of the data. This is valuable in terms of ensuring that the
manuscript is presented in a way
that makes sense to others, is visually appealing (in terms of figures),
and is maximally legible. Believe
it or not, a sizeable proportion of
manuscripts I have reviewed seem
unlikely to have been read by anyone other than maybe two of the

How to Get Published in a Peer-Reviewed Journal
Saturday, December 9, 2017, 11:15 a.m. - 12:15 p.m.
Georgia World Congress Center, Building B, Level 2, B213-B214
Chair: Bob Löwenberg, MD, PhD

Meet the Blood Editors: What Makes a Great Paper for Blood?
Sunday, December 10, 2017, 11:15 a.m. - 12:15 p.m.
Monday, December 11, 2017, 12:15 p.m. - 1:15 p.m.
Georgia World Congress Center, Building B, Level 4, B408

authors on the manuscript at most.
MD: A manuscript submitted
to Blood should contain novel information that will advance the
knowledge in a particular field,

while confirmatory reports may be
better suited for other journals. The
manuscript also should be written
clearly, with defined messages and
conclusions.

NOW APPROVED FOR THE TREATMENT OF
CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) IN
NEWLY DIAGNOSED AND RELAPSED/REFRACTORY PATIENTS1
TM

MYLOTARG™ (gemtuzumab ozogamicin) is indicated for the treatment of:
u Newly diagnosed CD33-positive AML in adults
u Relapsed/refractory CD33-positive AML in adults and pediatric patients
2 years and older
IMPORTANT SAFETY INFORMATION
WARNING: Hepatotoxicity, including severe or fatal hepatic veno-occlusive disease (VOD), also
known as sinusoidal obstruction syndrome (SOS), has been reported in association with the use
of MYLOTARG as a single agent, and as part of a combination chemotherapy regimen. Monitor
frequently for signs and symptoms of VOD after treatment with MYLOTARG.
Hepatotoxicity, Including Veno-occlusive Liver Disease (VOD): An increased risk of VOD was
observed in patients with moderate/severe hepatic impairment and patients who received
MYLOTARG either before or after HSCT. Assess ALT, AST, total bilirubin, and alkaline phosphatase
prior to each dose of MYLOTARG. After treatment with MYLOTARG, monitor frequently for signs
and symptoms of VOD; these may include elevations in ALT, AST, and total bilirubin, hepatomegaly,
rapid weight gain, and ascites. Monitoring only total bilirubin may not identify all patients at risk
of VOD. For patients who develop abnormal liver tests, more frequent monitoring of liver tests
and clinical signs and symptoms of hepatotoxicity is recommended. For patients who proceed to
HSCT, monitor liver tests frequently during the post-HSCT period, as appropriate. Manage signs
or symptoms of hepatic toxicity by dose interruption or discontinuation of MYLOTARG. In patients
who experience VOD, discontinue MYLOTARG and treat according to standard medical practice.
Infusion-Related Reactions (Including Anaphylaxis): Life-threatening or fatal infusion-related
reactions can occur during or within 24 hours following infusion of MYLOTARG. Signs and
symptoms of infusion-related reactions may include fever, chills, hypotension, tachycardia,
hypoxia, and respiratory failure. Premedicate prior to MYLOTARG infusion. Monitor vital signs
frequently during infusion. Interrupt infusion immediately for patients who develop evidence of
infusion reaction, especially dyspnea, bronchospasm, or hypotension. Monitor patients during and
for at least 1 hour after the end of the infusion or until signs and symptoms completely resolve.
Discontinue use of MYLOTARG in patients who develop signs or symptoms of anaphylaxis,
including severe respiratory symptoms or clinically significant hypotension.
Hemorrhage: MYLOTARG is myelosuppressive and can cause fatal or life-threatening hemorrhage
due to prolonged thrombocytopenia. Assess blood counts prior to each dose of MYLOTARG and
monitor blood counts frequently after treatment with MYLOTARG until resolution of cytopenias.
Monitor patients for signs and symptoms of bleeding during treatment with MYLOTARG. Manage
severe bleeding, hemorrhage, or persistent thrombocytopenia using dose delay or permanent
discontinuation of MYLOTARG, and provide supportive care per standard practice.

F:7.625"

Table of Contents for the Digital Edition of ASH News Daily 2017 - Issue 1